|Bid||50.39 x 900|
|Ask||50.40 x 1200|
|Day's range||50.26 - 51.42|
|52-week range||38.48 - 61.71|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||13.11|
|Earnings date||26 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||1.60 (3.12%)|
|Ex-dividend date||12 May 2022|
|1y target est||59.33|
Citi shares popped after Berkshire Hathaway announced it had acquired 55 million shares of the company, the FDA approved Pfizer's COVID booster for ages 5-11, and JD.com topped Q1 sales estimates despite China lockdowns.
For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. COVID-19 revenue has resulted in surging revenue for Pfizer.
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.